Abstract：
Acute kidney injury (AKI) is not only a worldwide problem with a cruel hospital mortality rate but also an independent risk factor for chronic kidney disease and a promoting factor for its progression. Despite supportive therapeutic measures, there is no effective treatment for AKI. This study employs tetrahedral framework nucleic acid (tFNA) as a vehicle and combines typhaneoside (Typ) to develop the tFNA-Typ complex (TTC) for treating AKI. With the precise targeting ability on mitochondria and renal tubule, increased antiapoptotic and antioxidative effect, and promoted mitochondria and kidney function restoration, the TTC represents a promising nanomedicine for AKI treatment. Overall, this study has developed a dual-targeted nanoparticle with enhanced therapeutic effects on AKI and could have critical clinical applications in the future.
摘要：
急性肾损伤（AKI）不仅是一个具有严重医院死亡率的世界性问题，而且是慢性肾脏病的独立危险因素和其进展的促进因素。尽管采取了支持性治疗措施，目前尚无有效的治疗方法。这项研究采用四面体框架核酸（tFNA）作为载体，并结合了伤寒苷（Typ）来开发用于治疗AKI的tFNA-Typ复合物（TTC）。具有对线粒体和肾小管的精确靶向能力，增加抗凋亡和抗氧化作用，促进线粒体和肾功能恢复，TTC代表了一种用于AKI治疗的有前途的纳米药物。总的来说,这项研究开发了一种双靶向纳米颗粒,对AKI的治疗效果增强,未来可能具有关键的临床应用.
